Beam Therapeutics (BEAM) Short term Debt (2019 - 2025)
Historic Short term Debt for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $6.5 million.
- Beam Therapeutics' Short term Debt fell 2261.9% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 2261.9%. This contributed to the annual value of $8.4 million for FY2024, which is 2222.22% down from last year.
- Beam Therapeutics' Short term Debt amounted to $6.5 million in Q3 2025, which was down 2261.9% from $3.9 million recorded in Q2 2025.
- Over the past 5 years, Beam Therapeutics' Short term Debt peaked at $85.4 million during Q2 2021, and registered a low of $3.9 million during Q2 2025.
- Moreover, its 5-year median value for Short term Debt was $13.6 million (2023), whereas its average is $22.9 million.
- As far as peak fluctuations go, Beam Therapeutics' Short term Debt soared by 59619.05% in 2021, and later crashed by 8079.63% in 2022.
- Quarter analysis of 5 years shows Beam Therapeutics' Short term Debt stood at $42.2 million in 2021, then plummeted by 56.64% to $18.3 million in 2022, then crashed by 40.98% to $10.8 million in 2023, then decreased by 22.22% to $8.4 million in 2024, then dropped by 22.62% to $6.5 million in 2025.
- Its Short term Debt stands at $6.5 million for Q3 2025, versus $3.9 million for Q2 2025 and $5.2 million for Q1 2025.